Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Inari's product portfolio complements Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.On Monday, Stryker Corporation (NYSE:SYK) agreed to acquire Inari Medical Inc. (NASDAQ:NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.
周一，斯特莱克公司（纽交所：SYK）同意以每股80美元的现金收购Inari Medical Inc.（纳斯达克：NARI），这代表了大约49亿的完全稀释股本价值。
Inari, founded in 2011, will help strengthen the peripheral vascular position in the growing segment of venous thromboembolism (VTE) to Stryker.
Inari成立于2011年，将有助于加强Stryker在日益增长的静脉血栓栓塞（VTE）领域的周边血管地位。
VTE is a term for blood clots in the veins, which can lead to serious illness, disability, or death.
VTE是指发生在静脉中的血栓，可能导致严重的疾病、残疾或死亡。
Inari's product portfolio complements Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Inari的产品组合补充了Stryker的神经血管业务，包括用于周边血管疾病（如深静脉血栓和肺栓塞）的机械取栓解决方案。
Also Read: Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
另请阅读：摩根士丹利在2024年面临挫折的情况下维持对医疗科技的积极展望，上调对直觉外科公司和Stryker的评级，下调对Nevro和Glaukos的评级。
Each year, VTE impacts up to 900,000 lives in the United States, with even more affected worldwide. Mechanical thrombectomy for VTE is an estimated $6 billion segment opportunity in the U.S. and is expected to grow 20%+ annually.
每年，VTE在美国影响多达900,000人，全球受影响人数更是更多。用于治疗VTE的机械取栓市场在美国的机会估计为60亿美元，预计年增长率超过20%。
Inari products are sold in 30+ countries, with 150,000+ patients treated for VTE.
Inari的产品在30多个国家销售，已对超过150,000名VTE患者进行了治疗。
Analysts estimate Inari's 2024 sales of around $603 million, reflecting 20%+ growth from 2023
分析师估计Inari在2024年的销售额约为60300万美元，比2023年增长超过20%。
People are at particularly high risk for this condition during or just after a hospitalization (with or without surgery), during cancer treatment, and during or just after pregnancy.
人们在住院（无论是否伴随手术）、接受癌症治疗和怀孕期间或刚刚怀孕后，尤其容易面临这种控件的高风险。
Inari provides solutions for VTE clot removal without the use of thrombolytic drugs.
Inari提供无溶栓药物的VTE血栓移除解决方案。
"The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases," said Kevin Lobo, Chair and CEO of Stryker. "These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker's impact in endovascular procedures."
Stryker董事长兼CEO Kevin Lobo表示：“收购Inari扩展了Stryker的产品组合，为患有外周血管疾病的患者提供挽救生命的解决方案。这些创新提高了静脉血栓栓塞患者的护理标准，并将加速Stryker在血管内手术中的影响。”
The transaction will be funded with cash on hand and debt and is expected to close by the end of the first quarter of 2025.
此次交易将通过手头现金和债务进行融资，预计将在2025年第一季度末完成。
Expected impacts to 2025 financial results will be discussed on Stryker's upcoming fourth quarter 2024 earnings call scheduled for January 28, 2025.
对2025年财务结果的预期影响将在Stryker即将于2025年1月28日举行的2024年第四季度业绩会上讨论。
Price Action: NARI stock is up 21% at $78.65, and SYK stock is down 1.76% at $355 during the premarket session at last check Tuesday.
价格动态：NARI股票上涨21%，达到78.65美元，而SYK股票在周二的盘前交易中下跌1.76%，达到355美元。
- Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
- 分析师表示，Viking Therapeutics和Structure Therapeutics成为减肥产品的关键制药合作伙伴。
